The U.K. drug regulator on Wednesday approved Amgen’s (NASDAQ ... placebo in over 280 adults with TED. A rare vision-threatening autoimmune disease impacting fat and muscle tissue around the ...

Uplizna was added to Amgen’s rare disease portfolio with the acquisition of Horizon Therapeutics in 2023. The drug generated sales worth $379 million in 2024.

Amgen has bagged a second indication for its B cell-depleting therapy Uplizna after the FDA cleared it for rare inflammatory disease IgG4-related disease (IgG4-RD). Acquired as part of its $27.8 ...

Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA. The biotech has ...

Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024 ...

April 3 (Reuters) - The U.S. Food and Drug Administration has approved expanded use of Amgen's (AMGN.O ... for Immunoglobulin G4-related disease (IgG4-RD), a rare condition in which an overactive ...

However, this continuous influx of new mutations comes at the expense of rare diseases ... treating and preventing disease. deCODE genetics is a wholly-owned subsidiary of Amgen.

Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.